Aprepitant in Adolescent Patients for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Tolerability

Background. The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents. Procedure. Patients age 11-19 years old receiving emetogenic chemotherapy were randomized 2:1 to aprepitant triple therapy (aprepitant [A] 125 mg p.o., dexamethasone [D] 8 mg p.o., and ondansetron [O]0.15 mg/kg i.v. t.i.d. day 1; A 80 mg, D 4 mg, and 0 0.15 mg/kgt.i.d. day 2; A 80 mg and D4 mg day 3; and D 4 mg day 4) or a control regimen (D 16 mg and 0 0.15 mg/kg t.i.d. day 1; D 8 mg and 0 0.15 mg/1